Seqens Seqens

X

Find the latest Drugs in Development and Pipeline Prospector News of Alkahest.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Alkahest
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
125 Shoreway Road, Suite D San Carlos, CA 94070
Telephone
Telephone
+1 (650) 801-0474
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

In the phase 2 clinical study of GRF6021 in subjects with PD and cognitive impairment, GRF6021 demonstrated positive effects on cognitive endpoints and was safe and well tolerated by study participants.


Lead Product(s): GRF6021

Therapeutic Area: Neurology Product Name: GRF6021

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Grifols International

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 08, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Alkahest currently has four candidates in six phase-2 clinical trials covering therapeutic products for neurodegenerative, cognitive decline, neuromuscular and ophthalmic indications .


Lead Product(s): Plasma-based therapies

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Partner/Sponsor/Collaborator: Grifols International

Deal Size: $146.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition September 07, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The company has dosed the first subject in AKST4290-205, which will assess the effects of AKST4290 on visual acuity with loading doses of anti-VEGF in treatment-naïve neovascular AMD patients.


Lead Product(s): AKST4290

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The trial, AKST4290-211, is funded in part by The Michael J. Fox Foundation for Parkinson’s Research and will evaluate the effect of AKST4290 on motor function in Parkinson’s disease.


Lead Product(s): AKST4290

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY